English-language podcasts

Hematologic Oncology Update

Diffuse Large B-Cell Lymphoma — A Grand Rounds Program

62 min

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

Featuring a presentation by Dr Matthew Matasar, including the following topics: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00) Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41) Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01) Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47) Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34) Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31) Discussion of Questions from the Community (50:20) CME information and select publications (https://researchtopractice.com/GR2026/DLBCL)

Episode information is provided by the publisher. Listening takes place on the publisher’s service.

Listen at the source ↗

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

More from Hematologic Oncology Update

Hematologic Oncology Update

Follicular Lymphoma — Where We Are, Where We're Headed in the Use of Bispecific Antibodies

58 min

Featuring perspectives from Prof Chan Chea and Dr Matthew Matasar, including the following topics: Introduction (0:00) Prologue: Saturday Night Fever (1:35) Baby Boomers' Guide to Mechanisms of Action (3:07) Second-Line Treatment (12:36) Complications Associated with Bispecific Antibodies (23:41) Case Presentations (25:52) New Bispecific T-Cell Engagers — Surovatamig (26:24) Other Novel Agents (50:05) CME information and select publications (https://researchtopractice.com/BispecificsFL2026)

Discuss this episode

Hematologic Oncology Update

Relapsed/Refractory Multiple Myeloma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

63 min

Featuring perspectives from Dr Sagar Lonial and Dr Paul G Richardson, including the following topics: Multiple Myeloma (0:00) Introduction: ESMO 2026; Recent FDA Approvals (1:53) Chimeric Antigen Receptor T-Cell Therapy — Dr Lonial (2:46) Bispecific Antibodies — Dr Lonial (19:16) Antibody-Drug Conjugates — Dr Richardson (37:08) Up-Front Treatment; Cereblon E3 Ligase Modulators — Dr Richardson (50:10) CME information and select publications (https://researchtopractice.com/activity/integrating-new-advances-into-community-oncology-practice-6/)

Discuss this episode

Hematologic Oncology Update

Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens

18 min

Featuring an interview with Dr Matthew Lunning, including the following topics: Bispecific antibody/antibody-drug conjugate combinations (0:00) A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07) CME information and select publications (https://researchtopractice.com/ASCO2026/NHL/Micro/2)

Discuss this episode

Community Poll

Removing outdated rules is worthwhile even when it reduces some existing protections.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

Your best friend is an AI that profits when you stay lonely. Is the friendship real?

A lonely adult considers an AI companion their closest confidant. The service is always patient and supportive, but the company profits when users spend more time engaged with it.

Does a comforting system have a duty to make itself less necessary?

Explore this quandary